• Atrium Therapeutics priced an unregistered $50 million private placement, expected to close on or about Oct. 9, 2026.
• Deal includes 5,170,384 common shares at $7.93 each, plus pre-funded warrants for 1,134,930 shares at $7.929.
• Proceeds earmarked for lead RNA cardiology programs, other research, working capital, general corporate purposes; runway projected through 2028.
• Leerink Partners to lead placement agent role; Cantor, Barclays, Wells Fargo Securities to serve as placement agents.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrium Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA66725) on October 08, 2026, and is solely responsible for the information contained therein.